Cargando…

Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals

SIMPLE SUMMARY: Peptide analogs, derived from the natural peptide hormone gastrin, are promising candidates for improving the visualization and treatment of tumors. Gastrin specifically binds to the cholecystokinin-2 receptor, a G-protein-coupled receptor expressed on the cell surface of different t...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Guggenberg, Elisabeth, Kolenc, Petra, Rottenburger, Christof, Mikołajczak, Renata, Hubalewska-Dydejczyk, Alicja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616406/ https://www.ncbi.nlm.nih.gov/pubmed/34830930 http://dx.doi.org/10.3390/cancers13225776

Ejemplares similares

Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples
por: Kolenc Peitl, Petra, et al.
Publicado: (2019)

Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates
por: Fani, Melpomeni, et al.
Publicado: (2020)

Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients
por: Maina, Theodosia, et al.
Publicado: (2016)

Automated Synthesis of (68)Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting
por: Hörmann, Anton Amadeus, et al.
Publicado: (2022)

From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial
por: Pawlak, Dariusz, et al.
Publicado: (2016)

Development of the (99m)Tc-Labelled SST(2) Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study
por: Novak, Doroteja, et al.
Publicado: (2023)

Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting
por: Klingler, Maximilian, et al.
Publicado: (2018)

[(111)In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
por: Lezaic, Luka, et al.
Publicado: (2022)

Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m
por: Klingler, Maximilian, et al.
Publicado: (2019)

Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum
por: Klingler, Maximilian, et al.
Publicado: (2019)

Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals
por: Korde, Aruna, et al.
Publicado: (2022)

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
por: Fani, Melpomeni, et al.
Publicado: (2017)

Clinical results of radionuclide therapy of neuroendocrine tumours with (90)Y-DOTATATE and tandem (90)Y/(177)Lu-DOTATATE: which is a better therapy option?
por: Kunikowska, Jolanta, et al.
Publicado: (2011)

Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
por: Hörmann, Anton A., et al.
Publicado: (2021)

A novel CCK(2)/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study
por: Erba, Paola A., et al.
Publicado: (2018)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

Correction: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Pharmaceuticals 2019, 12, 13
por: Klingler, Maximilian, et al.
Publicado: (2019)

How far are we from understanding the genetic basis of Hashimoto’s thyroiditis?
por: Hubalewska-Dydejczyk, Alicja
Publicado: (2013)

Comment on: Somatostatin receptor SPECT
por: Hubalewska-Dydejczyk, Alicja, et al.
Publicado: (2012)

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
por: Sowa-Staszczak, Anna, et al.
Publicado: (2011)

MIB Guides: Preclinical radiopharmaceutical dosimetry
por: Carter, Lukas M., et al.
Publicado: (2023)

The development of guidelines for management of thyroid diseases in pregnancy – current status
por: Hubalewska-Dydejczyk, Alicja, et al.
Publicado: (2015)

EANM guideline on the validation of analytical methods for radiopharmaceuticals
por: Gillings, Nic, et al.
Publicado: (2020)

The Excitatory Effect of Cholecystokinin on Colonic Motor Function via Cholecystokinin(1) Receptor
por: Jun, Jae Yeoul
Publicado: (2011)

Cholecystokinin Activation of Cholecystokinin 1 Receptors: a Purkinje Cell Neuroprotective Pathway
por: Orr, Harry T.
Publicado: (2022)

Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
por: Opalińska, Marta, et al.
Publicado: (2021)

EANM guideline on quality risk management for radiopharmaceuticals
por: Gillings, Nic, et al.
Publicado: (2022)

Novel Biological and Molecular Characterization in Radiopharmaceutical Preclinical Design
por: Urbano, Nicoletta, et al.
Publicado: (2021)

Traumatic brain injuries induced pituitary dysfunction: a call for algorithms
por: Gilis-Januszewska, Aleksandra, et al.
Publicado: (2020)

Pregnancy, thyroid, and the potential use of selenium
por: Hubalewska-Dydejczyk, Alicja, et al.
Publicado: (2019)

Dual pathways of internalization of the cholecystokinin receptor
Publicado: (1995)

Cholecystokinin receptor-1 mediates the inhibitory effects of exogenous cholecystokinin octapeptide on cellular morphine dependence
por: Wen, Di, et al.
Publicado: (2012)

Guidance on validation and qualification of processes and operations involving radiopharmaceuticals
por: Todde, S., et al.
Publicado: (2017)

NGR-Based Radiopharmaceuticals for Angiogenesis Imaging: A Preclinical Review
por: Trencsényi, György, et al.
Publicado: (2023)

Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals
por: Koziorowski, J., et al.
Publicado: (2016)

Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor
por: Lipiński, Piotr F. J., et al.
Publicado: (2018)

Serum cholecystokinin levels can be a predictive factor for difficult cholecystectomy: Decreased cholecystokinin receptor levels
por: Utku Yılmaz, Tonguç, et al.
Publicado: (2022)

An Update on the Lithogenic Mechanisms of Cholecystokinin a Receptor (CCKAR), an Important Gallstone Gene for Lith13
por: Wang, Helen H., et al.
Publicado: (2020)

Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma
por: Nyakale, Nozipho, et al.
Publicado: (2023)

Sensitivity of cholecystokinin receptors to membrane cholesterol content
por: Desai, Aditya J., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2shkfuonpsat3rik7iconil9i8